Prezcobix is owned by Janssen Prods.
Prezcobix contains Cobicistat; Darunavir.
Prezcobix has a total of 6 drug patents out of which 0 drug patents have expired.
Prezcobix was authorised for market use on 29 January, 2015.
Prezcobix is available in tablet;oral dosage forms.
Prezcobix can be used as treatment of hiv infection using a composition containing a pharmacokinetic enhancer that inhibits cytochrome p450 monooxygenase; treatment of hiv infection in adults and pediatric patients weighing at least 40kg using a composition containing a pharmacokinetic enhancer that inhibits cytochrome p450 monooxygenase.
The generics of Prezcobix are possible to be released after 06 October, 2032.
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US8518987 | JANSSEN PRODS | Pseudopolymorphic forms of a HIV protease inhibitor |
Feb, 2024
(8 months from now) | |
US7700645 | JANSSEN PRODS | Pseudopolymorphic forms of a HIV protease inhibitor |
Dec, 2026
(3 years from now) | |
US8148374 | JANSSEN PRODS | Modulators of pharmacokinetic properties of therapeutics |
Sep, 2029
(6 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8518987 (Pediatric) | JANSSEN PRODS | Pseudopolymorphic forms of a HIV protease inhibitor |
Aug, 2024
(1 year, 2 months from now) | |
US7700645 (Pediatric) | JANSSEN PRODS | Pseudopolymorphic forms of a HIV protease inhibitor |
Jun, 2027
(4 years from now) | |
US10039718 | JANSSEN PRODS | Use of solid carrier particles to improve the processability of a pharmaceutical agent |
Oct, 2032
(9 years from now) |
Drugs and Companies using COBICISTAT; DARUNAVIR ingredient
Market Authorisation Date: 29 January, 2015
Treatment: Treatment of hiv infection using a composition containing a pharmacokinetic enhancer that inhibits cytochrome p450 monooxygenase; Treatment of hiv infection in adults and pediatric patients weighing a...
Dosage: TABLET;ORAL
42
United States
24
European Union
17
Japan
16
Spain
13
Portugal
12
Korea, Republic of
12
Hungary
12
Australia
11
Slovenia
11
Lithuania
11
Denmark
11
Norway
10
China
10
Croatia
10
Cyprus
9
Poland
8
Hong Kong
8
EA
8
Singapore
7
New Zealand
6
Canada
6
AP
6
Mexico
5
ME
5
Brazil
5
Taiwan
5
RS
5
Argentina
4
Ukraine
3
South Africa
3
Israel
2
Luxembourg
2
Colombia
2
Ecuador
1
Chile
1
Peru
1
Netherlands
1
Uruguay
1
San Marino
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic